Top

Published in:

Open Access 01-12-2024 | Polycystic Ovary Syndrome | Research

Efficacy of optimal nutraceutical combination in treating PCOS characteristics: an in-silico assessment

Authors: Abha Saxena, Manali Sherkane, Rachana Bhoite, Manasa Premasudha Sadananda, Vinita Satyavrat, Venkatesh Kareenhalli

Published in: BMC Endocrine Disorders | Issue 1/2024

Abstract

Background

Polycystic ovary syndrome (PCOS) is a serious health condition affecting women of reproductive age. High prevalence of PCOS and associated metabolic complications needs effective treatment and management. This study evaluated the efficacy of optimal nutraceutical combinations in improving PCOS characteristics using system biology-based mathematical modelling and simulation.

Methods

A shortlisting of eight potent nutraceuticals was carried out with literature search. Menstrual cycle model was used to perform simulations on an in-silico population of 2000 individuals to test individual and combined effects of shortlisted nutraceuticals on five PCOS characteristics [oligomenorrhea, anovulation, hirsutism, infertility, and polycystic ovarian morphology (PCOM)] for a duration of 6 months. Efficacy was tested across lean and obese phenotypes and age groups.

Results

Individual assessment of nutraceuticals revealed seven most potent compounds. Myo-inositol among them was observed to be the most effective in alleviating the PCOS characteristics. The in-silico population analysis showed that the combination of melatonin and ALA along with myo-inositol was efficacious in restoring the hormonal balance across age-groups and Body Mass Index (BMI) categories.

Conclusion

Supplementation with the combination of myo-inositol, melatonin, and ALA demonstrated potential in managing PCOS symptoms in our in-silico analysis of a heterogeneous population, including lean and obese phenotypes across various severities and age groups, over a 6-month period. Future clinical studies are recommended to validate these findings.

Available only for authorised users

Liu J, Wu Q, Hao Y, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: global burden of Disease Study 2017. Hum Reprod. 2021;36(4):1108–19. https://doi.org/10.1093/HUMREP/DEAA371.CrossRefPubMedPubMedCentral

Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess Society Guideline. J Clin Endocrinol Metab. 2006;91(11):4237–45. https://doi.org/10.1210/JC.2006-0178.CrossRefPubMed

Mihanfar A, Nouri M, Roshangar L, Khadem-Ansari MH, Polyphenols. Natural compounds with promising potential in treating polycystic ovary syndrome. Reprod Biol. 2021;21(2). https://doi.org/10.1016/j.repbio.2021.100500.

Reyes-Muñoz E, Sathyapalan T, Rossetti P, et al. Polycystic ovary syndrome: implication for drug metabolism on assisted Reproductive Techniques—A. Literature Rev Adv Therapy 2018. 2018;35(11):11. https://doi.org/10.1007/S12325-018-0810-1.CrossRef

Mahran A. The relationship between Anti-müllerian hormone and the clinical, biochemical and sonographic parameters in women with polycystic ovarian syndrome. Middle East Fertil Soc J. 2016;21(1):11–5. https://doi.org/10.1016/j.mefs.2015.06.003.CrossRef

Chen W, Pang Y. Metabolic syndrome and PCOS: Pathogenesis and the role of metabolites. Metabolites. 2021;11(12). https://doi.org/10.3390/metabo11120869.

Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Reviews Disease Primers 2016. 2016;2(1):1. https://doi.org/10.1038/nrdp.2016.57.CrossRef

Ganie M, Vasudevan V, Wani I, Baba M, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J Med Res. 2019;150(4):333. https://doi.org/10.4103/IJMR.IJMR_1937_17.CrossRefPubMedPubMedCentral

Mehreen TS, Ranjani H, Kamalesh R, Ram U, Anjana RM, Mohan V. Prevalence of polycystic ovarian syndrome among adolescents and young women in India. J Diabetol. 2021;12(3):319. https://doi.org/10.4103/JOD.JOD_105_20.CrossRef

10.

Bahadur A, Mundhra R, Kashibhatla J, Rajput R, Verma N, Kumawat M. Prevalence of metabolic syndrome among women with different PCOS phenotypes - a prospective study. Gynecol Endocrinol. 2021;37(1):21–5. https://doi.org/10.1080/09513590.2020.1775193.CrossRefPubMed

11.

Tabassum F, Jyoti C, Sinha HH, Dhar K, Akhtar MS. Impact of polycystic ovary syndrome on quality of life of women in correlation to age, basal metabolic index, education and marriage. PLoS ONE. 2021;16(3). https://doi.org/10.1371/JOURNAL.PONE.0247486.

12.

Manique MES, Ferreira AMAP. Polycystic ovary syndrome in adolescence: challenges in diagnosis and management. Revista Brasileira De Ginecol E Obstet. 2022;44(4):425–33. https://doi.org/10.1055/S-0042-1742292/ID/JR210084-36.CrossRef

13.

Nayaker BS, Thomas S, Ramachandran S, Loganathan S, Sundari M, Mala K. Polycystic ovarian syndrome-associated cardiovascular complications: an overview of the association between the biochemical markers and potential strategies for their prevention and elimination. Diabetes Metabolic Syndrome: Clin Res Reviews. 2017;11:S841–51. https://doi.org/10.1016/j.dsx.2017.07.004.CrossRef

14.

Lashen H. Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010;1(3):117. https://doi.org/10.1177/2042018810380215.CrossRefPubMedPubMedCentral

15.

Jensterle M, Kravos NA, Ferjan S, Goricar K, Dolzan V, Janez A. Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocr Connect. 2020;9(1):44–54. https://doi.org/10.1530/EC-19-0449.CrossRefPubMed

16.

Santini A, Cammarata SM, Capone G, et al. Nutraceuticals: opening the debate for a regulatory framework. Br J Clin Pharmacol. 2018;84(4):659–72. https://doi.org/10.1111/BCP.13496.CrossRefPubMedPubMedCentral

17.

Gharaei R, Mahdavinezhad F, Samadian E, et al. Antioxidant supplementations ameliorate PCOS complications: a review of RCTs and insights into the underlying mechanisms. J Assist Reprod Genet. 2021;38(11):2817–31. https://doi.org/10.1007/s10815-021-02342-7.CrossRefPubMedPubMedCentral

18.

Zhang S, wei, Zhou J, Gober HJ, Leung WT, Wang L. Effect and mechanism of berberine against polycystic ovary syndrome. Biomed Pharmacotherapy. 2021;138:111468. https://doi.org/10.1016/j.biopha.2021.111468.CrossRef

19.

Li MF, Zhou XM, Li XL. The Effect of Berberine on Polycystic Ovary Syndrome Patients with Insulin Resistance (PCOS-IR): A Meta-Analysis and Systematic Review. Evidence-based Complementary and Alternative Medicine. 2018;2018. https://doi.org/10.1155/2018/2532935.

20.

Zilaee M, Mansoori A, Ahmad HS, Mohaghegh SM, Asadi M, Hormoznejad R. The effects of soy isoflavones on total testosterone and follicle-stimulating hormone levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reproductive Health Care. 2020;25(4):305–10. https://doi.org/10.1080/13625187.2020.1761956.CrossRef

21.

Poormoosavi SM, Behmanesh MA, Varzi HN, Mansouri S, Janati S. The effect of follicular fluid selenium concentration on oocyte maturation in women with polycystic ovary syndrome undergoing in vitro fertilization/intracytoplasmic sperm injection: a cross-sectional study. Int J Reprod Biomed. 2021;19(8):689–98. https://doi.org/10.18502/ijrm.v19i8.9616.CrossRef

22.

Li Y, Tan Y, Xia G, Shuai J. Effects of probiotics, prebiotics, and synbiotics on polycystic ovary syndrome: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2021;0(0):1–17. https://doi.org/10.1080/10408398.2021.1951155.CrossRef

23.

Unfer V et al. A deeper assessment of ω3-poly-unsaturated fatty acids in polycystic ovary syndrome management. Comment on regidor. chronic inflammation in PCOS: The potential benefits of specialized pro-resolving lipid mediators (SPMs) in the improvement of the re. Int J Mol Sci. 2021;22(18):14–16. https://doi.org/10.3390/ijms221810114.

24.

Mombaini E, Jafarirad S, Husain D, Haghighizadeh MH, Padfar P. The impact of Green Tea supplementation on anthropometric indices and inflammatory cytokines in women with polycystic ovary syndrome. Phytother Res. 2017;31(5):747–54. https://doi.org/10.1002/ptr.5795.CrossRefPubMed

25.

Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99–105. https://doi.org/10.1530/EJE-11-0616.CrossRefPubMed

26.

Giuliani C, Iezzi M, Ciolli L, et al. Resveratrol has anti-thyroid effects both in vitro and in vivo. Food Chem Toxicol. 2017;107:237–47. https://doi.org/10.1016/j.fct.2017.06.044.CrossRefPubMed

27.

Kort DH, Lobo RA. Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: a randomized controlled trial. Am J Obstet Gynecol. 2014;211(5):487e. 1-487.e6.CrossRef

28.

Hajimonfarednejad M, Nimrouzi M, Heydari M, Zarshenas MM, Raee MJ, Jahromi BN. Insulin resistance improvement by cinnamon powder in polycystic ovary syndrome: a randomized double-blind placebo controlled clinical trial. Phytother Res. 2018;32(2):276–83. https://doi.org/10.1002/ptr.5970.CrossRefPubMed

29.

Contreras-Bolívar V, García-Fontana B, García-Fontana C, Muñoz-Torres M. Mechanisms involved in the relationship between vitamin D and insulin resistance: impact on clinical practice. Nutrients. 2021;13(10):1–25. https://doi.org/10.3390/nu13103491.CrossRef

30.

Kaminska K, Grzesiak M. The relationship between vitamin d3 and insulin in polycystic ovary syndrome-a critical review. J Physiol Pharmacol. 2021;72(1):13–22. https://doi.org/10.26402/jpp.2021.1.02.CrossRef

31.

Heshmati J, Omani-Samani R, Vesali S, et al. The effects of supplementation with chromium on insulin resistance indices in women with polycystic ovarian syndrome: a systematic review and Meta-analysis of Randomized clinical trials. Horm Metab Res. 2018;50(3):193–200. https://doi.org/10.1055/S-0044-101835.CrossRefPubMed

32.

Sheikhhossein F, Amini MR, Shahinfar H, Djafari F, Safabakhsh M, Shab-Bidar S. Effects of chromium supplementation on inflammatory biomarkers: a systematic review and dose-response meta-analysis of randomized controlled trials. Eur J Integr Med. 2020;37(44):101147. https://doi.org/10.1016/j.eujim.2020.101147.CrossRef

33.

Pourteymour Fard Tabrizi F, Hajizadeh-Sharafabad F, Vaezi M, Jafari-Vayghan H, Alizadeh M, Maleki V. Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review. J Ovarian Res. 2020;13(1):1–10. https://doi.org/10.1186/s13048-020-0616-z.CrossRef

34.

Sadeghi A, Djafarian K, Mohammadi H, Shab-Bidar S. Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials. Diabetes Metabolic Syndrome: Clin Res Reviews. 2017;11(2):157–62. https://doi.org/10.1016/j.dsx.2016.06.025.CrossRef

35.

Hendrix AO, Hughes CL, Selgrade JF. Modeling endocrine control of the Pituitary–Ovarian Axis: androgenic influence and Chaotic dynamics. Bull Math Biol. 2014;76(1):136–56. https://doi.org/10.1007/s11538-013-9913-7.CrossRefPubMed

36.

Aversa A, La Vignera S, Rago R, et al. Fundamental concepts and novel aspects of polycystic ovarian syndrome: Expert consensus resolutions. Front Endocrinol (Lausanne). 2020;11(August):1–16. https://doi.org/10.3389/fendo.2020.00516.CrossRef

37.

Maleki V, Jafari-Vayghan H, Kashani A, et al. Potential roles of carnitine in patients with polycystic ovary syndrome: a systematic review. Gynecol Endocrinol. 2019;35(6):463–9. https://doi.org/10.1080/09513590.2019.1576616.CrossRefPubMed

38.

Guo YM, Sun TC, Wang HP, Chen X. Research progress of melatonin (MT) in improving ovarian function: a review of the current status. Aging. 2021;13(13):17930–47. https://doi.org/10.18632/aging.203231.CrossRefPubMedPubMedCentral

39.

Devi N, Boya C, Chhabra M, Bansal D. N-acetyl-cysteine as adjuvant therapy in female infertility: a systematic review and meta-analysis. J Basic Clin Physiol Pharmacol. 2021;32(5):899–910. https://doi.org/10.1515/jbcpp-2020-0107.CrossRef

40.

Zhang J, Xing C, Zhao H, He B. The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis. Gynecol Endocrinol. 2021;37(12):1063–71. https://doi.org/10.1080/09513590.2021.1926975.CrossRefPubMed

41.

Haghighatdoost F, Gholami A, Hariri M. Alpha-lipoic acid effect on leptin and adiponectin concentrations: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2020;76(5):649–57. https://doi.org/10.1007/s00228-020-02844-w.CrossRefPubMed

42.

Reed BG, Carr BR. The normal menstrual cycle and the control of Ovulation. Endotext. Published Online August 5, 2018.

43.

Chahal S, Goyal P, Sodhi R. Multiple molecular pathways unfolding the pathophysiology of polycystic ovary syndrome. Ann Rom Soc Cell Biol. 2021;25(1):3746–65.

44.

Gaziano JM, Hennekens CH, O’Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, High-Density Lipoprotein, and risk of myocardial infarction. Circulation. 1997;96(8):2520–5. https://doi.org/10.1161/01.CIR.96.8.2520.CrossRefPubMed

45.

Purohit S, Rai S, Kalvit S, Purohit S, Rai S, Kalvit S. Prevalence of polycystic ovarian syndrome and its association with circulatory gonadotropins (luteinizing hormone and follicle-stimulating hormone) and prolactin in different reproductive age groups: a brief survey. J Reproductive Healthc Med. 2021;2:8. https://doi.org/10.25259/JRHM_27_2020.CrossRef

46.

Regidor PA, Schindler AE, Lesoine B, Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm Mol Biol Clin Investig. 2018;34(2). https://doi.org/10.1515/hmbci-2017-0067.

47.

Costantino D, Minozzi G, Minozzi F, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13(2):105–10.PubMed

48.

Papaleo E, Unfer V, Baillargeon JP et al. Myo-Inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. http://dx.doi.org/101080/09513590701672405. 2009;23(12):700–3. https://doi.org/10.1080/09513590701672405.

49.

Tabatabaie M, Amiri S, Golestan M, Azadeh J, Sene A, Zandieh Z. The effect of Myo Inositol supplement on molecular regulation of folliculogenesis, steroidogenesis, and assisted reproductive technique outcomes in patients with polycystic ovarian syndrome. Mol Biol Rep. 2021;0123456789. https://doi.org/10.1007/s11033-021-06833-9.

50.

Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512–21. https://doi.org/10.26355/eurrev_201906_18223.CrossRefPubMed

51.

Russo M, Forte G, Oliva MM, Laganà AS, Unfer V. Melatonin and myo-inositol: supporting reproduction from the oocyte to birth. Int J Mol Sci. 2021;22(16). https://doi.org/10.3390/ijms22168433.

52.

Genazzani AD. Integrative treatment with inositols and lipoic acid for insulin resistance of PCOS. Gynecol Reproductive Endocrinol Metabolism. 2020;1(3):146–57.

53.

Mojaverrostami S, Asghari N, Sc M, Khamisabadi M, Khoei HH, Abbas A. The role of melatonin in polycystic ovary syndrome: a review production and hosting by knowledge E. Int J Reprod Biomed. 2019;17(12):865–82. https://doi.org/10.18502/ijrm.v17i12.5789.CrossRefPubMedPubMedCentral

54.

Liao B, Qiao J, Pang Y. Central Regulation of PCOS: abnormal neuronal-Reproductive-Metabolic circuits in PCOS Pathophysiology. Front Endocrinol (Lausanne). 2021;12:604. https://doi.org/10.3389/fendo.2021.667422.CrossRef

55.

Genazzani AD. Expert’s opinion: integrative treatment with inositols and lipoic acid for insulin resistance of PCOS– Gynecological and Reproductive Endocrinology & Metabolism. Published online 2020.

56.

Sharma P, Gupta V, Kumar K, Khetarpal P. Assessment of serum elements concentration and polycystic ovary syndrome (PCOS): systematic review and Meta-analysis. Biol Trace Elem Res Published Online January. 2022;14:1–12. https://doi.org/10.1007/S12011-021-03058-6/FIGURES/4.CrossRef

57.

Günalan E, Yaba A, Yılmaz B. The effect of nutrient supplementation in the management of polycystic ovary syndrome-associated metabolic dysfunctions: a critical review Elif. J Turk Ger Gynecol Assoc. 2018;19:220–52. https://doi.org/10.4274/jtgga.2018.0077.CrossRefPubMedPubMedCentral

Title: Efficacy of optimal nutraceutical combination in treating PCOS characteristics: an in-silico assessment
Authors: Abha Saxena
Manali Sherkane
Rachana Bhoite
Manasa Premasudha Sadananda
Vinita Satyavrat
Venkatesh Kareenhalli
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Hirsutism
Testosterone
Infertility
Infertility
Published in: BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-024-01571-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Correction: Association between serum osteocalcin and atherosclerosis in type-2 diabetes mellitus: a cross-sectional study

L-shaped association between the GA/HbA1c ratio and all-cause mortality in U.S. adults with NAFLD: a cross-sectional study from the NHANES 1999–2004

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males

Association between HDL cholesterol with diabetic retinopathy in diabetic patients: a cross-sectional retrospective study

GRADE-ADOLOPMENT of hyperthyroidism treatment guidelines for a Pakistani context

HbA1c changes in a deprived population who followed or not a diabetes self-management programme, organised in a multi-professional primary care practice: a historical cohort study on 207 patients between 2017 and 2019

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage